Patents by Inventor Christiaan Nicolaas KLIJN

Christiaan Nicolaas KLIJN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnostic and therapeutic methods for cancer
    Patent number: 11859252
    Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Christiaan Nicolaas Klijn, Shiva Malek, Ivana Yen
  • METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE
    Publication number: 20220090205
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Application
    Filed: June 1, 2021
    Publication date: March 24, 2022
    Inventors: Christiaan Nicolaas KLIJN, James LEE, David Hugh STOKOE, Robert GENTLEMAN, Florian GNAD, Leonard David GOLDSTEIN, Juliann CHMIELECKI, Ryan J. HARTMAIER
  • Methods for diagnosing and treating cancer by means of the expression status and mutational status of NRF2 and downstream target genes of said gene
    Patent number: 11066709
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 20, 2021
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Christiaan Nicolaas Klijn, James Lee, David Hugh Stokoe, Robert Gentleman, Florian Gnad, Leonard David Goldstein, Juliann Chmielecki, Ryan J. Hartmaier
  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    Publication number: 20200190596
    Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).
    Type: Application
    Filed: September 7, 2018
    Publication date: June 18, 2020
    Inventors: Christiaan Nicolaas KLIJN, Shiva MALEK, Ivana YEN
  • METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE
    Publication number: 20190218618
    Abstract: The invention provides methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF2 target genes. The invention also provides methods of treating cancer in a subject with a NRF2 pathway antagonist, wherein the subject expresses one or more NRF2 splice variants or overexpresses one or more NRF2 target genes.
    Type: Application
    Filed: December 21, 2018
    Publication date: July 18, 2019
    Inventors: Christiaan Nicolaas KLIJN, James LEE, David Hugh STOKOE, Robert GENTLEMAN, Florian GNAD, Leonard David GOLDSTEIN, Juliann CHMIELECKI, Ryan J. HARTMAIER